Login / Signup

[Adverse drug reactions reported to the Brazilian pharmacovigilance system from 2008 to 2013: descriptive study].

Daniel Marques MotaÁlvaro VigoRicardo de Souza Kuchenbecker
Published in: Cadernos de saude publica (2019)
The study aimed to analyze suspected adverse drug reactions reported to Brazil's pharmacovigilance system (Notivisa-medicamento) from 2008 to 2013. This was a descriptive study whose analytical units in the database were reports and drug-adverse reactions pairs. A total of 26,554 reports were identified, for a reporting rate of 22.8/million inhabitants/year. Reports in female patients prevailed (60.5%), as did white color/race (58.1%). Age ranged from 0 to 112 years (median = 46 years). Nearly one-third (32.5%) of suspected adverse drug reactions occurred in vulnerable populations (elderly and children). A total of 54,288 drug- adverse reactions pairs were analyzed, with a prevalence of severe adverse drug reactions (59.2%), featuring those that resulted in clinically important effects (83.1%). The most frequent drugs in severe adverse drug reactions belonged to groups L, antineoplastic and immunomodulating agents (32.1%), and J, general anti-infectious agents for systemic use (27%), while the most affected system-organ-class was conditions of the skin and related disorders (23.7%). Notivisa-medicamento is an important resource for producing warning signs and hypotheses on the safety of drugs marketed in Brazil. However, the reporting rate per million inhabitants/year was far lower than that described in middle and high-income countries.
Keyphrases
  • adverse drug
  • drug induced
  • electronic health record
  • emergency department
  • newly diagnosed
  • pulmonary embolism
  • young adults
  • early onset
  • physical activity
  • patient reported outcomes
  • community dwelling